News INmune Bio, Inc.

Equities

INMB

US45782T1051

Market Closed - Nasdaq Other stock markets 04:00:00 2024-06-05 pm EDT			5-day change	1st Jan Change
9.39 ^USD	+1.84%		-2.69%	-16.61%

May. 30	Sector Update: Health Care Stocks Higher in Afternoon Trading	MT
May. 30	INmune Bio to Join Russell 3000 Index in July	MT

Summary

Unlock all the news: Be the first to know and act before the market!

100% Free Registration

Sector Update: Health Care Stocks Higher in Afternoon Trading	May. 30	MT
INmune Bio to Join Russell 3000 Index in July	May. 30	MT
INmune Bio Inc. to Join Russell 3000® Index	May. 30	GL
Earnings Flash (INMB) INMUNE BIO Reports Q1 Revenue $14,000	May. 09	MT
Transcript : INmune Bio, Inc., Q1 2024 Earnings Call, May 09, 2024	May. 09
INmune Bio Inc. Announces First Quarter 2024 Results and Provides Business Update	May. 09	AQ
INmune Bio, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	May. 09	CI
INmune Bio Inc. to Report First Quarter 2024 Financial Results and Provide a Corporate Update on Thursday, May 9	May. 07	GL
INmune Bio Inc. to Report First Quarter 2024 Financial Results and Provide a Corporate Update on Thursday, May 9	May. 07	AQ
INmune Bio Inc. Provides Update on Two Patients from the Phase 1b Alzheimer’s Disease Trial who Continue to Receive XPro™ Under Compassionate Use for Over Three Years	Apr. 30	GL
INmune Bio, Inc. Provides Update on Two Patients from the Phase 1b Alzheimer's Disease Trial	Apr. 30	CI
INmune Bio Inc. Completes First Cohort and Initiates Second Cohort of Phase 1/2 Study of INKmune™ Natural Killer Cell Therapy in Patients with Metastatic Castration-Resistant Prostate Cancer	Apr. 29	GL
INmune Bio Inc. Completes First Cohort and Initiates Second Cohort of Phase 1/2 Study of INKmune?? Natural Killer Cell Therapy in Patients with Metastatic Castration-Resistant Prostate Cancer	Apr. 29	CI
INmune Bio Inc. Announces $9.7 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules	Apr. 25	GL
INmune Bio Inc. Announces $9.7 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules	Apr. 25	AQ
INmune Bio Inc. Announces 24-Month Stability Validation of XPro for Phase III Readiness and Commercial Supply Chain Modeling and Development of Novel Immunogenicity Assay	Apr. 24	AQ
INmune Bio Inc. Raises Approximately $4.8 Million in Gross Proceeds through Registered Direct Offering with Officers, Employees and Directors Purchasing Approximately 20% of the Offering	Apr. 23	AQ
INmune Bio Inc. Announces 24-Month Stability Validation of XPro™ for Phase III Readiness and Commercial Supply Chain Modeling & Development of Novel Immunogenicity Assay	Apr. 23	GL
Inmune Bio Inc. Announces 24-Month Stability Validation of Xpro? for Phase III Readiness and Commercial Supply Chain Modeling & Development of Novel Immunogenicity Assay	Apr. 23	CI
INmune Bio Inc. Raises Approximately $4.8 Million in Gross Proceeds Through Registered Direct Offering with Officers, Employees and Directors Purchasing Approximately 20% of the Offering	Apr. 22	GL

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

News INmune Bio, Inc.

Equities

INMB

US45782T1051

Summary

Filters